Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Efficacy and Safety of Nirmatrelvir/Ritonavir in the Treatment of the Omicron Variant of COVID-19

NCT05813600 is registered in ClinicalTrials.gov with Xiangao Jiang as lead sponsor.

NCT NCT05813600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05813600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Efficacy and Safety of Nirmatrelvir/Ritonavir in the Treatment of the Omicron Variant of COVID-19
Lead sponsor
Xiangao Jiang
Phase
Not applicable
Overall status
Completed
Start date
August 31, 2022
Completion date
December 31, 2022
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

omicron variant of covid-19